Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P. Blagden, Essam Ghazaly, Ivana Rizzuto et al.|British Journal of Cancer|2018Cited by 43
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian CancerFarasat Kazmi, Sarah P. Blagden, René L. Roux et al.|Clinical Cancer Research|2021Cited by 10
Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumorsEssam Ghazaly, Sarah P. Blagden, P. Spilipoulou et al.|Annals of Oncology|2017Cited by 4
Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the alfa-pump closed system in platinum-resistant ovarian cancer (PROC): First clinical experience in a cancer patient.Christina Fotopoulou, Hani Gabra, Emily Pickford et al.|Journal of Clinical Oncology|2013Cited by 2
PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancerSarah P. Blagden, Essam Ghazaly, Ajithkumar Sukumaran et al.|Annals of Oncology|2017Cited by 2